Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 8/20 | 0.34 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75440 | 0.80 | — | — | |
| SCHEMBL22687353 | 0.80 | ITGB3 (0.41) | ITGB3ITGA2BALDH1A1MEN1KMT2A | |
| SCHEMBL1782023 | 0.80 | LMNA (0.47) | ITGB3ITGA2BEPHX2ALDH1A1LMNA | |
| Methane SCHEMBL27880200 | 0.78 | — | — | |
| Bicarbonate SCHEMBL10725172 | 0.78 | ITGB3 (0.41) | ITGB3ITGA2BALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7602448 | 0.78 | — | — | |
| SCHEMBL28956884 | 0.78 | — | — | |
| SCHEMBL515555 | 0.76 | ALDH1A1 (0.47) | EPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL187018 | 0.76 | — | — | |
| SCHEMBL15553833 | 0.74 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121108015-A | Synthesis method of Fmoc-L- (4, 4-difluorocyclohexyl) glycine | 吉尔生物(北戴河新区)有限公司 | 2025-12-12 | — | — | CN | disclosed |
| CN-121108015-A | Synthesis method of Fmoc-L- (4, 4-difluorocyclohexyl) glycine | 吉尔生物(北戴河新区)有限公司 | 2025-12-12 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8907092-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8835393-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8609845-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1836201-A1 | PYRROLIDINE INHIBITORS OF IAP | Genentech, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007106192-A2 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| CN-101035802-A | Inhibitors of IAP | GENENTECH INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1778718-A1 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060167066-A1 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| WO-2006069063-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006014361-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ITGB3 4849/4885ITGA2B 4821/4885EPHX2 3594/4885 |
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | ITGB3 4366/4885ITGA2B 4097/4885EPHX2 4157/4885 |
| US-20060167066-A1 | Pyrrolidine inhibitors of IAP | BIRC5, XIAP, BIRC2 | ITGB3 4810/4885ITGA2B 4686/4885EPHX2 4202/4885 |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | ITGB3 4814/4885ITGA2B 4700/4885EPHX2 4205/4885 |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | BIRC5, BIRC2, XIAP | ITGB3 4396/4885ITGA2B 3892/4885EPHX2 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.